Products
Latest News
FAQ
|
Search
Search
Filters
Clear All
Study Phase
Early Phase 1
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase 4
Not Applicable
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Completed
Suspended
Terminated
Withdrawn
Study Type
Interventional
Observational
Expanded Access
Others
Eligibility Sex
All
Female
Male
Healthy Volunteers
All
Include
Exclude
Found
1
clinical trials
|
View Analysis
Sort by:
Newest First
A Study of KL340399 in Patients With Advanced Solid Tumors
Phase 1
Recruiting
Conditions
Advanced Solid Tumors
Interventions
Drug: KL340399 injection
Subscribe
First Posted Date
2022-05-24
Last Posted Date
2024-06-27
Lead Sponsor
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Target Recruit Count
30
Registration Number
NCT05387928
Locations
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Subscribe
Prev
1
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy